Journal of Gynecologic Oncology

Korean Society of Gynecologic Oncology (대한부인종양학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical significance of tumor volume and lymph node involvement assessed by MRI in stage IIB cervical cancer patients treated with concurrent chemoradiation therapy

Lee, Dae-Woo;Kim, Young-Tae;Kim, Jae-Hoon;Kim, Sung-Hoon;Kim, Sang-Wun;Nam, Eun-Ji;Kim, Jae-Wook

  • Published : 20100300
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study was to evaluate the prognostic significance of tumor volume assessed by pretreatment MRI in stage IIB cervical cancer patients with concurrent chemoradiation therapy. Methods: A retrospective chart review was performed on seventy five patients with cervical cancer who were treated with concurrent weekly cisplatin (40 mg/$m^{2}$) and radiotherapy between January 2000 and April 2007. Potential prognostic factors were age, chemotherapy numbers, histology, tumor diameter and volume, lymph node (LN) involvement and pretreatment squamous cell carcinoma antigen (SCC-Ag) levels. Results: The median follow-up time was 55 months (range, 8 to 104 months). The median tumor size and volume (range) were 4.5 cm (2 to 10) and 33.1 mL (4.2 to 392.7), respectively. Pelvic LN enlargement rate was 58.7%. Para-aortic LN enlargement rate was 14.7%. Using multivariate analysis, a tumor volume (>33 mL, p=0.025), pelvic LN enlargement (p=0.044) revealed a significantly unfavorable outcome on overall survival. PFS was influenced by tumor histology (p<0.001), pelvic LN enlargement (p=0.015) and pretreatment SCC-Ag levels (p=0.018). We found that 22 (29.3%) patients had recurrences and 14 (18.7%) patients died of disease. The 5-year overall survival rate was 80.6% (standard error, 4.9%) and 5-year PFS rate was 71.3% (standard error, 5.3%). Conclusion: Tumor volume and pelvic LN involvement showed possibility to predict overall survival in patient with stage ⅡB cervical cancer. Optimal tumor volume and pelvic LN assessment by pretreatment MRI might be helpful to predict treatment outcome.

Keywords

References

  1. Hricak H, Yu KK. Radiology in invasive cervical cancer. AJR Am J Roentgenol 1996; 167: 1101-8 https://doi.org/10.2214/ajr.167.5.8911159
  2. National Cancer Institute. NCI issues clinical announcement on cervical cancer: chemotherapy plus radiation improves survival. Bethesda: National Cancer Institute; 1999
  3. Eifel PJ, Morris M, Wharton JT, Oswald MJ. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994; 29: 9-16 https://doi.org/10.1016/0360-3016(94)90220-8
  4. Burghardt E, Baltzer J, Tulusan AH, Haas J. Results of surgical treatment of 1028 cervical cancers studied with volumetry. Cancer 1992; 70: 648-55 https://doi.org/10.1002/1097-0142(19920801)70:3<648::AID-CNCR2820700318>3.0.CO;2-R
  5. Micke O, Bruns F, Schafer U, Prott FJ, Willich N. The impact of squamous cell carcinoma (SCC) antigen in patients with advanced cancer of uterine cervix treated with (chemo-)radiotherapy. Anticancer Res 2005; 25: 1663-6
  6. Ogino I, Nakayama H, Okamoto N, Kitamura T, Inoue T. The role of pretreatment squamous cell carcinoma antigen level in locally advanced squamous cell carcinoma of the uterine cervix treated by radiotherapy. Int J Gynecol Cancer 2006; 16: 1094-100 https://doi.org/10.1111/j.1525-1438.2006.00449.x
  7. Scheidler J, Heuck AF. Imaging of cancer of the cervix. Radiol Clin North Am 2002; 40: 577-90 https://doi.org/10.1016/S0033-8389(01)00007-0
  8. Amendola MA, Hricak H, Mitchell DG, Snyder B, Chi DS, Long HJ 3rd, et al. Utilization of diagnostic studies in the pretreatment evaluation of invasive cervical cancer in the United States: results of intergroup protocol ACRIN 6651/GOG 183. J Clin Oncol 2005; 23: 7454-9 https://doi.org/10.1200/JCO.2004.00.5397
  9. Thoms WW Jr, Eifel PJ, Smith TL, Morris M, Delclos L, Wharton JT, et al. Bulky endocervical carcinoma: a 23-year experience. Int J Radiat Oncol Biol Phys 1992; 23: 491-9 https://doi.org/10.1016/0360-3016(92)90003-Z
  10. Ebner F, Tamussino K, Kressel HY. Magnetic resonance imaging in cervical carcinoma: diagnosis, staging, and follow-up. Magn Reson Q 1994; 10: 22-42
  11. Narayan K, McKenzie A, Fisher R, Susil B, Jobling T, Bernshaw D. Estimation of tumor volume in cervical cancer by magnetic resonance imaging. Am J Clin Oncol 2003; 26: e163-8 https://doi.org/10.1097/01.coc.0000091358.78047.b5
  12. Oellinger JJ, Blohmer JU, Michniewicz K, Siewert C, Wust P, Gutberlet M, et al. Pre-operative staging of cervical cancer: comparison of magnetic resonance imaging (MRI) and computed tomography (CT) with histologic results. Zentralbl Gynakol 2000; 122: 82-91
  13. Zaino RJ, Ward S, Delgado G, Bundy B, Gore H, Fetter G, et al. Histopathologic predictors of the behavior of surgically treated stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Cancer 1992; 69: 1750-8 https://doi.org/10.1002/1097-0142(19920401)69:7<1750::AID-CNCR2820690717>3.0.CO;2-S
  14. Choi SH, Kim SH, Choi HJ, Park BK, Lee HJ. Preoperative magnetic resonance imaging staging of uterine cervical carcinoma: results of prospective study. J Comput Assist Tomogr 2004; 28: 620-7 https://doi.org/10.1097/01.rct.0000138007.77725.0a
  15. Yu KK, Hricak H, Subak LL, Zaloudek CJ, Powell CB. Preoperative staging of cervical carcinoma: phased array coil fast spin-echo versus body coil spin-echo T2-weighted MR imaging. AJR Am J Roentgenol 1998; 171: 707-11
  16. Kawagoe T, Kashimura M, Matsuura Y, Sugihara K, Toki N, Aoki T. Clinical significance of tumor size in stage IB and II carcinoma of the uterine cervix. Int J Gynecol Cancer 1999; 9: 421-6 https://doi.org/10.1046/j.1525-1438.1999.99059.x
  17. Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with Stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer 1999; 85: 1547-54 https://doi.org/10.1002/(SICI)1097-0142(19990401)85:7<1547::AID-CNCR16>3.0.CO;2-2
  18. Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, et al. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand 2002; 81: 1144-51 https://doi.org/10.1034/j.1600-0412.2002.811208.x
  19. Tinga DJ, Timmer PR, Bouma J, Aalders JG. Prognostic significance of single versus multiple lymph node metastases in cervical carcinoma stage IB. Gynecol Oncol 1990; 39: 175-80 https://doi.org/10.1016/0090-8258(90)90428-N
  20. Inoue T, Morita K. The prognostic significance of number of positive nodes in cervical carcinoma stages IB, IIA, and IIB. Cancer 1990; 65: 1923-7 https://doi.org/10.1002/1097-0142(19900501)65:9<1923::AID-CNCR2820650909>3.0.CO;2-M
  21. Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, et al. Histopathologic prognostic factors in stage IIb cervical carcinoma treated with radical hysterectomy and pelvic-node dissection: an analysis with mathematical statistics. Int J Gynecol Cancer 1993; 3: 219-25 https://doi.org/10.1046/j.1525-1438.1993.03040219.x
  22. Suprasert P, Srisomboon J, Kasamatsu T. Radical hysterectomy for stage IIB cervical cancer: a review. Int J Gynecol Cancer 2005; 15: 995-1001 https://doi.org/10.1111/j.1525-1438.2005.00259.x
  23. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999; 17: 41-5 https://doi.org/10.1200/JCO.1999.17.1.41
  24. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001; 11: 263-71 https://doi.org/10.1046/j.1525-1438.2001.011004263.x
  25. Mayr NA, Taoka T, Yuh WT, Denning LM, Zhen WK, Paulino AC, et al. Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 2002; 52: 14-22 https://doi.org/10.1016/S0360-3016(01)01808-9
  26. Hatano K, Sekiya Y, Araki H, Sakai M, Togawa T, Narita Y, et al. Evaluation of the therapeutic effect of radiotherapy on cervical cancer using magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1999; 45: 639-44 https://doi.org/10.1016/S0360-3016(99)00228-X
  27. Lea JS, Sheets EE, Wenham RM, Duska LR, Coleman RL, Miller DS, et al. Stage IIB-IVB cervical adenocarcinoma: prognostic factors and survival. Gynecol Oncol 2002; 84: 115-9 https://doi.org/10.1006/gyno.2001.6473
  28. Molina R, Filella X, Lejarcegui JA, Pahisa J, Torne A, Rovirosa A, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumour Biol 2003; 24: 156-64 https://doi.org/10.1159/000073846

Cited by

  1. Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. vol.42, pp.6, 2010, https://doi.org/10.1093/ejcts/ezs136
  2. Outcomes and prognostic factors of cervical cancer after concurrent chemoradiation vol.38, pp.11, 2010, https://doi.org/10.1111/j.1447-0756.2012.01871.x
  3. Advanced Imaging Applications for Locally Advanced Cervical Cancer vol.13, pp.5, 2010, https://doi.org/10.7314/apjcp.2012.13.5.1713
  4. Early diffusion weighted magnetic resonance imaging can predict survival in women with locally advanced cancer of the cervix treated with combined chemo-radiation vol.22, pp.11, 2010, https://doi.org/10.1007/s00330-012-2496-0
  5. Squamous cell carcinoma antigen vol.119, pp.13, 2010, https://doi.org/10.1002/cncr.28055
  6. RAMAN SPECTROSCOPIC STUDY ON PREDICTION OF TREATMENT RESPONSE IN CERVICAL CANCERS vol.6, pp.2, 2010, https://doi.org/10.1142/s1793545813500144
  7. Prognostic Impact of Histology in Patients with Cervical Squamous Cell Carcinoma, Adenocarcinoma and Small Cell Neuroendocrine Carcinoma vol.14, pp.9, 2010, https://doi.org/10.7314/apjcp.2013.14.9.5355
  8. Histological type-specific prognostic factors of cervical small cell neuroendocrine carcinoma, adenocarcinoma, and squamous cell carcinoma vol.7, pp.None, 2010, https://doi.org/10.2147/ott.s64714
  9. Comparison of the Prognostic Value of F-18 Pet Metabolic Parameters of Primary Tumors and Regional Lymph Nodes in Patients with Locally Advanced Cervical Cancer Who Are Treated with Concurrent Chemora vol.10, pp.9, 2010, https://doi.org/10.1371/journal.pone.0137743
  10. Measurement of tumor volume is not superior to diameter for prediction of lymph node metastasis in early gastric cancer with minute submucosal invasion vol.8, pp.69, 2010, https://doi.org/10.18632/oncotarget.22894
  11. Regulatory roles of miRNA-758 and matrix extracellular phosphoglycoprotein in cervical cancer vol.14, pp.4, 2010, https://doi.org/10.3892/etm.2017.4887
  12. Prognostic value of intratumoral metabolic heterogeneity on F-18 fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced cervical cancer patients treated with concurren vol.8, pp.52, 2010, https://doi.org/10.18632/oncotarget.18769
  13. Outcome and prognostic factors in cervical cancer patients treated with surgery and concurrent chemoradiotherapy: a retrospective study vol.16, pp.None, 2010, https://doi.org/10.1186/s12957-017-1307-0
  14. Strain elastography as an early predictor of long-term prognosis in patients with locally advanced cervical cancers treated with concurrent chemoradiotherapy vol.30, pp.1, 2020, https://doi.org/10.1007/s00330-019-06345-y
  15. Prognosis-Predicting Model Based on [ 18 F]fluorodeoxyglucose PET Metabolic Parameters in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy: Multi-Center R vol.9, pp.2, 2010, https://doi.org/10.3390/jcm9020427
  16. Improving the Prognostic Performance of SUV max in 18 F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Using Tumor-to-Liver and Tumor-to-Blood Standard Upt vol.9, pp.6, 2010, https://doi.org/10.3390/jcm9061878
  17. Correlations of UICC tumor stage and tumor regression on T2-weighted MRI sequences during definitive radiotherapy of cervical cancer vol.107, pp.2, 2010, https://doi.org/10.1177/0300891620940024